671. Why Has There Been So Little Progress on Alzheimer’s Disease?

This episode of Freakonomics Radio investigates the stalled progress in Alzheimer's disease research, revealing a systemic crisis rooted in flawed science, institutional complacency, and conflicts of interest. Journalist Charles Piller and neuroscientist Matthew Schrag uncover decades of scientific misconduct, including image manipulation and data fabrication, in high-profile Alzheimer's studies. The dominant amyloid cascade hypothesis—centered on beta-amyloid plaques as the primary cause—has consumed billions in research funding, yet has failed to produce effective treatments. Schrag’s whistleblowing efforts exposed fraudulent work at Cassava Sciences and the University of Minnesota, leading to retractions, federal investigations, and the downfall of key figures like Hao Yan Wang and Eliezer Maslia. The episode also critiques regulatory capture, where FDA officials later joined the very companies they once regulated, and highlights how the field’s obsession with amyloid has diverted attention from other promising avenues like vascular health and waste clearance in the brain. Despite the setbacks, Schrag offers cautious hope, advocating for a broader, more integrated approach to neurodegenerative disease research. The episode concludes with a call for scientific integrity, transparency, and humility. Schrag reflects on the personal cost of whistleblowing, including strained relationships with mentors like Othman Grebe, whose early work he later found compromised. Piller emphasizes that while science is inherently difficult, the field must confront its own arrogance and protect public trust. The overarching message is that Alzheimer’s is not a single-disease problem but a complex, multifactorial condition requiring diverse strategies—ranging from blood vessel health to environmental factors—rather than a singular, flawed hypothesis. The future of treatment lies not in doubling down on failed models, but in embracing complexity, accountability, and a more inclusive scientific culture.